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Abstract
The proportions of new cancer cases and deaths that are caused by exposure to risk factors and that 
could be prevented are key statistics for public health policy and planning. This paper summarizes 
the methodologies for estimating, challenges in the analysis of, and utility of, population 
attributable and preventable fractions for cancers caused by major risk factors such as tobacco 
smoking, dietary factors, high body fat, physical inactivity, alcohol consumption, infectious 
agents, occupational exposure, air pollution, sun exposure, and insufficient breastfeeding. For 
population attributable and preventable fractions, evidence of a causal relationship between a risk 
factor and cancer, outcome (such as incidence and mortality), exposure distribution, relative risk, 
theoretical-minimum-risk, and counterfactual scenarios need to be clearly defined and congruent. 
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Despite limitations of the methodology and the data used for estimations, the population 
attributable and preventable fractions are a useful tool for public health policy and planning.
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Introduction
The impacts of behavioral and environmental risk factors on disease have long been studied, 
and quantifying such impacts has been a major public health objective in order to guide 
prevention and policy [1, 2]; specifically, for cancer [3]. The proportion of an outcome that 
would have not occurred in a population over a given period of time by decreasing a 
population‘s exposure to a risk factor, firstly to a theoretical-minimum-risk, and secondly to 
an attainable level, are known respectively as the population attributable fraction (PAF) and 
the population preventable fraction (PPF) [4]. The attributable fraction was developed by 
Levin in 1953 for estimation of the “maximum proportion of lung cancer attributable to 
smoking” [2]. It was further elaborated on in the 1970s [5–8] when the etiologic fraction (a 
similar but conceptually distinct fraction) was developed [1]. At the same time, the concept 
of a preventable fraction, defined as the potential proportion of outcomes that was prevented 
by a protective risk factor, was introduced [1]; however, the the current definition of a 
preventable fraction differs from this original definition [9]. The methodologies to estimate 
cancer PAFs and PPFs continue to develop, differ by subtype, and are dependent on etiology 
[10, 11]. Accordingly, this review aims to provide updated and globally applicable 
methodologies for linking risk factors to cancer incidence and mortality.
Population attributable and preventable fraction studies
Numerous, national, regional, and international PAF and PPF estimation studies have 
estimated the attributable and/or preventable cancers due to either a specific risk factor or 
multiple risk factors. Risk factors are selected based on the level of evidence for a causal 
relationship, relevancy of the risk factors for population health, availability and quality of 
population-representative data, and if the risk factors are avoidable [10–12]. The 
Comparative Risk Assessment (CRA) studies require sufficient causal evidence [13]; see 
also [14, 15] for an outline of the different levels of causal evidence. Commonly studied 
factors include tobacco smoking, diet, alcohol consumption, infectious agents, occupational 
exposure, air pollution, sun exposure (ultraviolet radiation (UVR)), insufficient or decreased 
duration of breastfeeding, body mass index (BMI) (a measure of body fat), and physical 
inactivity [10, 11]. Among infectious agents, relevancy is a large consideration: for example, 
in a United Kingdom study [10], infections of clonorchis sinensis, opisthorchis viverrini and 
schistosoma haematobium were excluded because of their low infection rate [16]. Other risk 
factors, including oral contraceptive use, hormone replacement therapy (HRT), lack of 
aspirin use, and medical radiation exposure [10, 11] have also been assessed; however, 
interpretation of the burden caused by these factors is challenging due to the effects of these 
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risk factors on other aspects of health [10, 11]. Lastly, risk factors for cancer such as number 
of births and age at first birth [17] are generally not modelled as policies changing these risk 
factors are not politically acceptable in many countries [18].
Methods to estimate the population attributable and preventable fractions
The PAFs and PPFs are estimated by comparing the risk of cancer for populations under past 
and/or current conditions as compared to a counterfactual scenario [19]. For the PAFs, the 
population risk under the counterfactual scenario is the theoretical-minimum-risk (see Box 1 
for a definition). However, for the PPFs, the population risk under the counterfactual 
scenario is the risk exposure distribution that is attainable (either through the achievement of 
a health target (see [20]) or through the implementation of one or various policies [21]). The 
main differences between PAFs and PPFs are outlined in Table 1. See Box 1 for an overview 
of PAF and PPF terminology.
The PAFs and PPFs can be estimated, firstly, using cohort or case-control data from 
population representative studies, secondly, using exposure data among cases (where the 
cases are representative of the population) combined with relative risk (RR) data, or, thirdly, 
through separate data sources on the prevalence of exposure to a risk factor and the 
corresponding RR (most common method). This review focuses on the third method to 
estimate PAFs and PPFs. In addition to these methods, other risk factor-specific methods 
(see section on smoking, UVR and infections) are also briefly summarized.
Specifying the theoretical-minimum-risk and the counterfactual scenario
For the PAFs, the counterfactual scenario is based on everyone having a theoretical-
minimum-risk exposure. The theoretical-minimum-risk exposure is usually defined as the 
exposure distribution leading to the lowest population risk of morbidity and/or mortality 
[22], which is generally no exposure to that risk factor, e.g., lifetime never smokers. 
However, there are exceptions: for example, for BMI, a BMI of zero is not possible, hence 
the theoretical-minimum-risk is a BMI distribution that leads to the lowest cancer risk (see 
Figure 1). For factors such as physical inactivity or fibre consumption, the counterfactual is 
often to have everyone physically active or consuming a sufficient amount of fibre [23]. 
Finally, for alcohol, the theoretical-minimum-risk exposure is generally lifetime abstention, 
even though low levels of alcohol consumption have an overall protective effect on total 
mortality (See Figure 2) [24].
For the PPFs, the counterfactual scenario is determined based on an attainable exposure 
distribution (see [19, 25]). These exposure distributions are achieved either through 
intervention(s), such as an increase in taxation (for alcohol and tobacco) or vaccination 
programs (for infectious agents), or through the exposure distribution reaching a 
predetermined target (e.g., Global Monitoring Framework for non-communicable diseases 
targets [26]). Attainable targets can also be defined as the level of an exposure that is 
observed in other populations [27], or in the same population at a different point in time 
[28]. Exposure changes due to interventions are usually modelled based on the results of 
studies that examine how these interventions affect the exposure distribution (which should 
take into account the potential participation rate if applicable [29]) [30, 31]. Another utility 
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of the PPF is its use in assessing cost-effectiveness, and, to determine the cost-effective 
minimum, the intervention(s) that produce the maximum health gain for the lowest 
economic cost. In high-income countries, the cost effectiveness can be assessed using the 
cost of saving one Quality Adjusted Life Year (QALY) according to NICE guidelines 
(20,000 to 30,000 British pounds or an equivalent per QALY saved) [32].
Specifying the outcome
Incidence, mortality, years of life lost due to premature mortality, and years lived with 
disability are the most common outcomes modelled using PAFs and PPFs [33]. The PAFs 
and PPFs can also be used to estimate attributable and preventable Disability Adjusted Life 
Years (DALYs) [34], QALYs, and monetary costs by applying the PAFs and PPFs to lower 
level components of these measures. Other outcomes include resources (such as hospital 
days and/or stays) [33]. These statistics are important when determining public policy and 
allocating health resources; however, the choice of the outcome(s) modelled is dependent on 
data availability as well as the goal of the project [33].
Specifying the exposure
When estimating the PAFs and PPFs, the time between exposure and outcome i.e., the 
biological latency period (time lag) should be considered. For example, in the case of 
tobacco smoking, there is a time lag of approximately 30 years between exposure and the 
diagnosis of cancer [35]. Furthermore, for occupational exposure and the incidence of solid 
tumors, there is a 20- to 50-year time lag [36–38], while for occupational exposures and the 
incidence of hematological cancer, there is a 10- to 20-year time lag [39, 40]. Conversely, for 
HRT (estrogen plus progestin) use and the incidence of breast cancer, there is assumed to be 
a very short time lag [41, 42]. In some cases, no time lag is used to facilitate comparisons 
between different diseases [43]. Therefore, there is a need to carefully consider the issue of 
latency, and also to clearly document the latency period chosen to enable comparisons 
between studies.
The population exposure can be modelled using a categorical or continuous distribution. 
Categorical exposure estimates are sometimes used when population surveys report 
exposures within categories, or when RR estimates are reported for categorical measures of 
exposure. The precision of PAFs and PPFs when using categorical estimates is dependent on 
the number of categories used. For BMI and cancer, a previous study showed small 
differences in estimations of cancers attributable to a high BMI when using a categorical 
distribution as compared to a continuous distribution [28, 44]. The impact on other risk 
factors need to be further determined. Additionally, when a continuous exposure distribution 
is used, the distribution may need to be truncated or bounded to prevent the modelling of 
exposure at unrealistic levels (see [45]).
Specifying the relative risk
When estimating PAFs based on different data sources, where possible, the risk data should 
be from meta-analyses (or large cohort studies), and consistent with the available exposure 
and outcome data in terms of the categories of exposure or the units of measurement used 
(for the exposure and RR data) and the outcome measured (for the RR and the outcome). 
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This is a problem for environmental exposure PAF and PPF estimations, in particular where 
RRs for high exposures are commonly applied to people with low exposures [46]. 
Furthermore, RRs affected by population level genetics should use population-specific RRs 
where possible. For example, in the case of excess BMI and breast cancer, the RR is below 1 
for Caucasian women and above one for Asian women [47].
The reference category for the RR measures, the PAF estimations, is the theoretical-
minimum-risk, whereas in the PPF estimations, the RR reference category can either be the 
theoretical-minimum-risk or a risk category with the preventative target exposure status. 
Similar to the population exposure, RRs can be modelled using categorical or continuous 
exposure distributions. If only RR point estimates are provided, the continuous functions can 
be modelled using either a linear RR, a log-linear RR, or a log-logit RR (see Figure 2 for an 
example). The choice of which model to use is dependent on the biological relationship, and 
on the methods used to estimate the RRs (or the methods used to estimate the underlying 
RRs upon which a meta-analysis is based). An alternative to these approaches is to model 
the exposure based on weighted observations from a survey, such that the estimation of the 
counterfactual is done at the survey participant level (see [48] for an example).
Differences in the risks of cancer among various sub-populations and across cancer subtypes 
need to be accounted for, if possible. For example, the RR for an exposure can vary by the 
histological subtype of cancer at a particular organ site (e.g., for esophageal cancer, obesity 
is only a cause of adenocarcinomas [49], whereas alcohol consumption is only a cause of 
squamous cell carcinomas [50]); however, due to the rarity of certain cancers, RRs are 
commonly reported for aggregate cancer sites. The effects of various risk factors on cancer 
incidence may deviate by sex, age [51], or life stage (e.g., there is an increased breast cancer 
risk caused by risk factor exposure between menarche and menopause due to the 
susceptibility of undifferentiated nulliparous breast tissue to carcinogens [52]). There also 
may be differences in RRs among people with genetic variations (e.g., people with the 
ALDH 2 genotype have a much greater risk of cancer due to alcohol consumption [53]), 
with the size of the effect of these genetic variations dependent upon the size of the effect 
modification and the prevalence of the genetic variation in the population. Lastly, risk 
reversibility and risk accumulation also may need to be taken into account when modelling 
PAFs and PPFs [54].
Other methods of estimating the population attributable and preventable fractions
Tobacco smoking—The PAF for smoking can be modelled using the Lopez and Peto 
methodology [55], where lung cancer mortality rates are used as a proxy for tobacco 
smoking. The Lopez and Peto method assesses differences in lung cancer mortality between 
a population of interest and a counterfactual population of never smokers. The difference in 
mortality is then assumed to be attributable to smoking and is used as a proxy for exposure 
to tobacco smoking when estimating the PAFs for other cancers. Many studies have used the 
American Cancer Prevention Study (CPS) phase II cohort as the counterfactual population 
when using this method. Lung cancer rates of never smokers between countries are, for the 
most part, quite similar where data are available [56]. The exception to this observation was 
found in countries where other strong risk factors for lung cancer are present, such as in 
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China where indoor and outdoor air pollution greatly affect lung cancer rates, in particular 
among women [57, 58]. To adjust for these other strong lung cancer risk factors [59], 
correction factors have been applied, but, generally, it is perceived that the Lopez and Peto 
method is not valid in settings where smoking prevalence is low, i.e., in many developing 
countries. Furthermore, the choice of the correction factor to be applied to adjust for other 
confounding factors has been a contentious issue. In the original Lopez and Peto paper, the 
correction factor was 50%, which has changed several times since the method was first 
published [55].
Preston and colleagues present an alternative method of estimating the PAF for tobacco 
smoking and total mortality, based on lung cancer mortality rates relative to total mortality 
rates [60]. This method applies a regression model to estimate the relationship between lung 
cancer mortality and total mortality by age, sex, and year to derive the PAF of total mortality 
due to tobacco smoking. This method avoids the utilization of RRs, and, thus, provides more 
flexibility. However, this method can only be applied to data from countries with similar 
distributions of causes of death to those countries used in the Preston and colleagues‘ study, 
and where there are no other strong lung cancer risk factors besides smoking (such as air 
pollution). Accordingly, this method is not suitable for PAF estimations for developing 
countries.
Infectious Agents—The PAFs and PPFs for infectious agents are based on an estimation 
of the proportion of cancer cases that would not have occurred if all or some of the 
infections had been avoided or successfully treated before oncogenesis [16]. These fractions 
are estimated through three different methods. Firstly, for HTLV-1 in adult T-cell lymphoma, 
and KSHV in Kaposi sarcoma, the infections are necessary causes of cancer and, thus, all of 
these cancers are attributable to the infections [16]. HPV in cervical cancer is also included 
in this model as non-HPV-related cervical cancers are rare. Secondly, for HPV (at other 
cancer sites) and Epstein-Barr virus-related cancers, these infectious agents are sufficient 
causes of cancer, with very high RRs (see [16]) and, thus, the prevalence of transcriptional 
viral gene products in tumor cells is used as a direct measure of the PAFs [16]. Lastly, 
helicobacter pylori, and Hepatitis B and C viruses are neither sufficient nor necessary cancer 
causes and, thus, the PAFs for cancers caused by these infectious agents are estimated based 
on the prevalence of transcriptional viral gene products in tumor cells and the RR of cancer 
given infection [16]. The infection status among cancer cases is obtained from pathological 
tests, and, therefore, depends largely on the techniques used, the infectious agent, and the 
cancer examined (see [16] for a more detailed explanation).
Sun exposure (ultraviolet radiation)—The PAF and PPF fractions for skin melanoma 
due to sun UVR are usually estimated using a direct method based on differences of skin 
melanoma rates between populations [61, 62] (for artificial UVR exposure such as sunbeds, 
traditional PAF and PPF estimation methods are used). For the sun exposure-PAFs, the 
theoretical-minimum-risk exposure has previously been estimated using the incidence of 
melanoma at body sites which are not exposed to UVR [62]. For the sun exposure-PPFs, 
which are considered to be more relevant due to the absence of an ‘unexposed’ population 
[61], the incidence of melanoma in reference areas or during a time period, (e.g., a historical 
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cohort of lower sun exposure) is used as a counterfactual [61, 62]. This latter method is seen 
as the most relevant, as it provides PPFs which are contextually appropriate for population 
comparisons. Lastly, the PPFs of skin melanoma and keratinocyte cancers due to sun 
exposure, assuming an increase in sunscreen use, can be modelled by combining data on 
sunscreen use, the RR of melanoma and keratinocyte cancers for people who use sunscreen 
compared to those who do not, and the number of preventable or attributable cancers 
estimated using one of the previously described methodologies [63].
Other considerations
Relative Risks
Current PAF and PPF formulas assume the use of a RR; however, studies often report odds 
ratios. An odds ratio can be used as an approximation of the risk ratio; however, it may 
overestimate the effect size of the RR (i.e., the distance by which the RR deviates from the 
null (i.e., 1)) when the incidence of an outcome of interest is not rare within the exposure 
group [64]. In such cases, a conversion of the odds ratio to a RR is desirable [64].
Commonly, risk factors are not found to be independent of one another [65]. For example, 
for cancer it is common to find a clustering of lifestyle unhealthy lifestyles [66], especially 
among a portion of the population, e.g., lower socio-economic strata [67]. However, the 
original attributable fraction formula described by Levin is considered valid only in the 
absence of confounding and/or effect modification [68, 69]. In cases of confounding, 
estimates of the attributable cancer burden based on an adjusted RR due to a risk factor of 
interest are likely to misestimate the true PAFs, the extent to which is dependent on the 
magnitude of confounding. In the case of effect modification, the estimation of PAFs is more 
complex. For example, moderate cigarette smoking or moderate alcohol consumption alone 
have a negligible effect on esophageal cancer risk; however, in combination they have a 
synergistically larger effect on esophageal cancer risk [70]. To account for the correlation of 
risk factor exposure, ideally the multivariate distribution of exposure to all risk factors can 
be used when estimating the PAFs. Additionally, in the presence of confounding or effect 
modification, the PAFs can be presented for people of different groups stratified by the 
confounding or effect modifying factors [28]. However, most data sources do not provide 
data on the joint exposure distribution. Alternatively, in the presence of confounding, the 
formula presented in Box 1 can also be used; however, this formula requires knowledge of 
the exposure among cases [68, 71]. Therefore, given the lack of data needed to adjust the 
PAFs for risk factor correlation, PAFs are generally estimated not taking confounding into 
account [72].
Cancers attributable to multiple risk factors
The PAFs and PPFs for multiple risk factors cannot be estimated through the simple addition 
of the PAFs and PPFs for the individual risk factors [73]. The PAFs and PPFs due to 
multiple risk factors can be estimated using the standard PAF functions using the prevalence 
distribution and RRs for co-occurring risk factors. However, this method requires data on co-
occurrence of the risk factors, and the relationship between risk factors [74]. Alternatively, 
assuming that risk factors are independent of each other, a PAF for multiple risk factors can 
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be estimated using case exposure data [75], or the formula presented by Miettinen [1] (see 
Box 1).
Uncertainty estimation
Due to the use of data from multiple sources to estimate the PAFs and PPFs, the uncertainty 
of these estimates is often determined using a Monte Carlo approach, where a set of the 
lowest level parameters used in these estimations is generated from their respective 
uncertainty distributions (taking into account variation between the parameters). These 
lowest level parameters are then used to estimate the uncertainty distribution of the PAFs 
and PPFs [76].
Limitations or challenges
As previously mentioned, the time lag between exposure and outcome in some cases is as 
long as 50 years. Besides the challenge of retrieving high quality historical data that are 
consistently measured across time (which is particularly problematic for disease 
classification, especially malignant lymphomas), the cancer risk factors may affect the risk 
of competing causes of death [77]; however, current methods rarely account for changes in 
mortality rates among those who are exposed to different sets of risk factors.
PAF and PPF estimates are restricted by time and population and depend on the quality and 
representativeness of the exposure and risk data. Data for risk factor exposure usually are 
obtained from population surveys [78] that often may not be representative of the population 
due to recruitment and participation biases [79, 80] and exclusion of subsets of the general 
population, such as the institutionalized and homeless [79, 80]. Furthermore, the questions 
on risk exposure may be limited by the respondents‘ comprehension of the questions asked, 
recall of the information, and possible deliberate misreporting of information (especially for 
socially negative behaviors [81, 82]). In some cases, the exposure as measured by a survey 
can be adjusted to match the population level exposure (as is the case with alcohol 
consumption [83]) (see Figure 2). For RR estimations, a source of exposure measurement 
bias is the potential for misclassification within the theoretical-minimum-risk reference 
group [84]. For example, Zeisser and colleagues showed that meta-analyses of the 
relationship between breast cancer and alcohol are affected by misclassification of 
occasional drinkers as lifetime abstainers, which leads to a small, yet significant, decrease in 
the RR estimates [85].
Discussion
The estimation of the proportion of cancer incidence and mortality attributable to various 
risk factors, as well as the proportion that could be prevented, provides useful information 
for health planning and setting health priorities by creating a hierarchy of cancer risk factors 
and interventions [86]. Current and previous PAF and PPF studies [10, 11, 28, 87, 88] have 
provided important information to set cancer prevention priorities, such as the new United 
Nations sustainable goals [89] or the national cancer prevention campaign [90, 91]. 
Furthermore, these studies can inform policy through establishing future health targets by 
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calculating PPFs using data from prediction models [20, 92] or established automated tools 
[30, 93].
The accuracy of PAFs and PPFs greatly depends on the quality of the underlying exposure 
and RR data. Therefore, there is a need to support initiatives at the national and international 
level in order to improve both risk factor and cancer surveillance systems, as these data are 
required for planning, implementing, and evaluating cancer prevention and control efforts 
[94]. Current multi-national risk factor surveillance systems include the Global Information 
System on Alcohol and Health [95] and the CAREX survey database for monitoring 
occupational exposures to carcinogens [96]. Furthermore, to strengthen cancer surveillance, 
the Global Initiative for Cancer Registry Development in low- and middle-income countries 
(GICR, http://gicr.iarc.fr) provides the necessary technical support and training to cancer 
registries to ultimately increase global coverage of high quality population-based cancer 
incidence data.
Many of the risk factors for cancer are also risk factors for other diseases, conditions and 
injuries [57], and changes in these risk factors may also have social and monetary effects. 
Therefore, it is imperative to consider the effects of changes in these risk factors on health 
conditions other than cancer and on social factors [77]. For example, to re-enforce the 
effects of prevention strategies, the estimation of the effects of prevention strategies on 
multiple disease may be desirable. Furthermore, changes in risk factors that are taxable 
products (such as tobacco and alcohol) to preventable targets may result in decreases in state 
revenues; however, decreases in health care expenditures and increases in productivity 
achieved through the reduction of these risk factors are likely to far outweigh losses in state 
revenues [97, 98].
Conclusion
When performing PAF and PPF studies, it is important to clearly describe the methods used, 
including data sources and assumptions made, to ensure replicability and transparency, and 
to highlight the limitations of these estimates in their applicability to health policy. Studies 
estimating attributable and preventable cancer burdens also provide an opportunity for cross-
disciplinary collaboration in order to ensure this translational research is reflected in public 
health policies.
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Population attributable fraction (PAF) and population preventable fraction 
(PPF) terminology
Attributable case (excess case): A case that would not have occurred if the person was 
not exposed to a given risk factor.
Attributable benefit: The fraction by which the occurrence of a disease of interest 
would be increased under an alternative exposure distribution.
Comparative Risk Assessment: The systematic evaluation of changes in population 
health which result from modifying the population distribution of exposure to a risk 
factor or a group of risk factors.
Counterfactual: An alternative scenario for a given place and time that has already past, 
whereby conditions of the scenario that has already occurred are altered (such as a cancer 
risk exposure which then results in a different number of cancer incident and mortality 
cases).
Excess risk model: A method of estimating the attributable or preventable fraction based 
on the number of observed cases as compared to the number of expected cases (based on 
either a predictive model or data from a reference population). This method is employed 
for smoking-attributable fractions and for sun exposure-attributable fractions, and is 
approximated using the following formula:
where casesobs represents the cases under the factual scenario and casesexpected represents 
the expected number of cases.
Impact risk: The success rate in changing the risk factor through an intervention 
program.
Impact number: The relative efficacy of the intervention, that is, the extent to which a 
successful change in a risk factor results in a risk reduction to the risk level of persons 
never exposed.
Population attributable fraction: The fraction by which the occurrence of a disease of 
interest would be reduced under an alternative exposure distribution (or counterfactual) 
during a given period in a given population. This exposure distribution is the theoretical-
minimum-risk.
Population preventable fraction: The fraction by which the occurrence of a disease of 
interest would be reduced under an alternative exposure distribution (or counterfactual) 
during a given period and in a given population. This exposure distribution is achieved 
through the implementation of interventions or through achieving health targets.
PAF and PPF formulas:
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Categorical exposure based PAF or PPF:
Continuous exposure based PAF:
Case based (for adjusted RR) PAF:
Combination of multiple PAFs:
where P represents the prevalence, PD represents the prevalence of cases where there was 
exposure to a risk factor and RR represents the relative risk given either xc or xcf which 
represents the current exposure distribution and the counterfactual exposure distribution 
respectively (either categorically or continuously). For the combination formula, T 
represents the total PAF or PPF, and n represents a risk factor-specific PAF or PPF. See 
[68] for other commonly used PAF formulas.
Theoretical-minimum-risk: The level of exposure to a risk factor that would result in 
the lowest overall burden.
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An example of the exposure distribution of Body Mass Index (based on the mean and 
standard deviation (SD)) and the corresponding continuous generic Relative Risks (RRs) 
(Figure from [28])
Shield et al. Page 18














Example of the exposure distribution of alcohol consumption among current drinkers (in 
grams of pure alcohol per day) before and after adjustment for undercoverage (for French 
men 35 to 44 years of age in 2005 as obtained from the Baromètre [99] and the Global 
Information System on Alcohol and Health [95]) and the Relative Risks (RRs) for liver 
cancer [100]
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Table 1
Population attributable fractions compared to population preventable fractions as applied to cancer risk factor 
surveillance and to cancer policy projection
Input/ Output Population attributable fraction Population preventable fraction
Reference exposure scenario The current or historical exposure
distribution in the entire population
The current or historical exposure
distribution in the entire population
Reference exposure group (reference
group for the RR used)
Theoretical-minimum-risk Theoretical-minimum-risk
Counterfactual scenario Everyone at the theoretical-
minimum-risk
Counterfactual scenario of an
attainable decrease in risk factor
exposure (e.g., an exposure decrease
through the implementation of an
intervention or through the
achievement of a health target)
Outcomes Deaths, years of life lost, years lived
with disability, Disability Adjusted
Life Years, Quality Adjusted Life
Years, monetary units, health
resources (such as hospital stays)
Deaths, years of life lost, years lived
with disability, Disability Adjusted
Life Years, Quality Adjusted Life
Years, monetary units, health
resources (such as hospital stays)
Main aim Estimate the proportion of an
outcome that would not be present in
a given population under the
assumption that everyone had the
theoretical-minimum-risk for a given
risk factor during a specified time
period
Assess the impact of implementing
interventions and/or reaching health
targets on an outcome for a given
population during a specified time
period








These terms also appear with the word “population” preceding the term to denote that the fraction/proportion are estimated for a given population, 
whereas without the term “population” the term can refer to the cancer cases within a cohort or case series attributable to a given risk factor.
**
Etiological fraction has been previously used as the proportion of cases that would have occurred by a certain time even in the absence of 
exposure, but, with exposure, occurred earlier than they otherwise would have. Although distinct conceptually from the attributable fraction, based 
on this definition, all attributable cases are etiologic cases, but not vice versa [73].
***
This term also appears with the word “theoretical” preceding the term to denote that the fraction/proportion is based on a theoretical scenario.
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